Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Constellation Pharmaceuticals Inc (CNST)

Constellation Pharmaceuticals Inc (CNST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 202,609
  • Shares Outstanding, K 25,810
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,930 K
  • 60-Month Beta 4.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.81
  • Number of Estimates 5
  • High Estimate -0.80
  • Low Estimate -0.83
  • Prior Year -0.81
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.46 +17.49%
on 08/23/19
8.91 -14.81%
on 09/12/19
-0.35 (-4.41%)
since 08/16/19
3-Month
6.46 +17.49%
on 08/23/19
12.99 -41.57%
on 06/28/19
-2.39 (-23.95%)
since 06/18/19
52-Week
4.01 +89.51%
on 12/31/18
14.04 -45.94%
on 03/28/19
+1.09 (+16.77%)
since 09/18/18

Most Recent Stories

More News
Constellation Pharmaceuticals to Participate in Two Investor Conferences

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company...

CNST : 7.59 (-3.31%)
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results

-- Data presented at ASCO and EHA suggest potential disease-modifying activity of CPI-0610 across the spectrum of myelofibrosis (MF) parameters, with multiple potential pathways for approval

CNST : 7.59 (-3.31%)
Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar...

CNST : 7.59 (-3.31%)
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host an analyst/investor...

CNST : 7.59 (-3.31%)
Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller, Senior Scientist at Constellation Pharmaceuticals, presented a poster titled Targeting epigenetic dysregulation...

CNST : 7.59 (-3.31%)
Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts

-- Data published in two abstracts suggest that CPI-0610 may have potential disease-modifying effects in treating myelofibrosis

CNST : 7.59 (-3.31%)
Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced its first-quarter...

CNST : 7.59 (-3.31%)
Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar...

CNST : 7.59 (-3.31%)
Report: Exploring Fundamental Drivers Behind The Cooper Companies, Encompass Health, SilverCrest Metals, Constellation Pharmaceuticals, Leaf Group, and TESSCO Technologies -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of The Cooper Companies, Inc. (NYSE:COO),...

SVCMF : 2.2600 (+1.80%)
EHC : 63.22 (-0.60%)
COO : 303.10 (-0.80%)
CNST : 7.59 (-3.31%)
LFGR : 11.15 (-0.89%)
SILV : 5.38 (-5.61%)
TESS : 14.43 (-1.16%)
LEAF : 4.24 (-4.50%)
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting

-- Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patients

CNST : 7.59 (-3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade CNST with:

Business Summary

Constellation Pharmaceuticals, Inc. operates as a bio-pharmaceutical company. It discovers and develops molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. The company's lead product candidates consists of CPI-1205, which inhibits enhancer of zeste homolog 2 and...

See More

Key Turning Points

2nd Resistance Point 8.46
1st Resistance Point 8.03
Last Price 7.59
1st Support Level 7.12
2nd Support Level 6.64

See More

52-Week High 14.04
Fibonacci 61.8% 10.21
Fibonacci 50% 9.02
Fibonacci 38.2% 7.84
Last Price 7.59
52-Week Low 4.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar